BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 29748441)

  • 1. Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease.
    Muller J; Bolomsky A; Dubois S; Duray E; Stangelberger K; Plougonven E; Lejeune M; Léonard A; Marty C; Hempel U; Baron F; Beguin Y; Cohen-Solal M; Ludwig H; Heusschen R; Caers J
    Haematologica; 2018 Aug; 103(8):1359-1368. PubMed ID: 29748441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma.
    Bolomsky A; Heusschen R; Schlangen K; Stangelberger K; Muller J; Schreiner W; Zojer N; Caers J; Ludwig H
    Haematologica; 2018 Feb; 103(2):325-335. PubMed ID: 29122991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia.
    Zhang Y; Zhou X; Li Y; Xu Y; Lu K; Li P; Wang X
    Oncogene; 2018 Oct; 37(41):5520-5533. PubMed ID: 29895969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
    Gan ZY; Fitter S; Vandyke K; To LB; Zannettino AC; Martin SK
    Eur J Haematol; 2015 Apr; 94(4):343-54. PubMed ID: 25179233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.
    Heusschen R; Muller J; Binsfeld M; Marty C; Plougonven E; Dubois S; Mahli N; Moermans K; Carmeliet G; Léonard A; Baron F; Beguin Y; Menu E; Cohen-Solal M; Caers J
    Oncotarget; 2016 May; 7(21):30712-29. PubMed ID: 27095574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma.
    Maes A; Maes K; Vlummens P; De Raeve H; Devin J; Szablewski V; De Veirman K; Menu E; Moreaux J; Vanderkerken K; De Bruyne E
    Blood Cancer J; 2019 Nov; 9(12):87. PubMed ID: 31740676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in osteosarcoma.
    Jeddo SFA; Wei X; Li K; Li X; Yang Q; Dongol S; Li J
    Oncol Rep; 2020 Sep; 44(3):1037-1048. PubMed ID: 32705239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic Kinases.
    Ji W; Arnst C; Tipton AR; Bekier ME; Taylor WR; Yen TJ; Liu ST
    PLoS One; 2016; 11(4):e0153518. PubMed ID: 27082996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel carbon-11 radiolabeled maternal embryonic leucine zipper kinase inhibitor for PET imaging of triple-negative breast cancer.
    Tang R; Gai Y; Li K; Hu F; Gong C; Wang S; Feng F; Altine B; Hu J; Lan X
    Bioorg Chem; 2021 Feb; 107():104609. PubMed ID: 33454507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells.
    Kohler RS; Kettelhack H; Knipprath-Mészaros AM; Fedier A; Schoetzau A; Jacob F; Heinzelmann-Schwarz V
    Gynecol Oncol; 2017 Apr; 145(1):159-166. PubMed ID: 28214016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MELK Inhibition in Diffuse Intrinsic Pontine Glioma.
    Meel MH; de Gooijer MC; Guillén Navarro M; Waranecki P; Breur M; Buil LCM; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso A; Bugiani M; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
    Clin Cancer Res; 2018 Nov; 24(22):5645-5657. PubMed ID: 30061363
    [No Abstract]   [Full Text] [Related]  

  • 12. The crystal structure of MPK38 in complex with OTSSP167, an orally administrative MELK selective inhibitor.
    Cho YS; Kang Y; Kim K; Cha YJ; Cho HS
    Biochem Biophys Res Commun; 2014 Apr; 447(1):7-11. PubMed ID: 24657156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells.
    Stefka AT; Park JH; Matsuo Y; Chung S; Nakamura Y; Jakubowiak AJ; Rosebeck S
    Blood Cancer J; 2016 Aug; 6(8):e460. PubMed ID: 27540718
    [No Abstract]   [Full Text] [Related]  

  • 14. [
    Hu F; Gong C; Gai Y; Jiang D; Liu Q; Wang S; Hu M; Pi R; Shu H; Hu J; Lan X
    Mol Pharm; 2021 Sep; 18(9):3544-3552. PubMed ID: 34482695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MEK/MELK inhibition and blood-brain barrier deficiencies in atypical teratoid/rhabdoid tumors.
    Meel MH; Guillén Navarro M; de Gooijer MC; Metselaar DS; Waranecki P; Breur M; Lagerweij T; Wedekind LE; Koster J; van de Wetering MD; Schouten-van Meeteren N; Aronica E; van Tellingen O; Bugiani M; Phoenix TN; Kaspers GJL; Hulleman E
    Neuro Oncol; 2020 Jan; 22(1):58-69. PubMed ID: 31504799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elucidating the Role of the Maternal Embryonic Leucine Zipper Kinase in Adrenocortical Carcinoma.
    Kiseljak-Vassiliades K; Zhang Y; Kar A; Razzaghi R; Xu M; Gowan K; Raeburn CD; Albuja-Cruz M; Jones KL; Somerset H; Fishbein L; Leong S; Wierman ME
    Endocrinology; 2018 Jul; 159(7):2532-2544. PubMed ID: 29790920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma.
    Martin SK; Gan ZY; Fitter S; To LB; Zannettino AC
    Leuk Res; 2015 Mar; 39(3):380-7. PubMed ID: 25624048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
    Kupisiewicz K
    Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant.
    Simon M; Mesmar F; Helguero L; Williams C
    PLoS One; 2017; 12(2):e0172832. PubMed ID: 28235006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MELK promotes Endometrial carcinoma progression via activating mTOR signaling pathway.
    Xu Q; Ge Q; Zhou Y; Yang B; Yang Q; Jiang S; Jiang R; Ai Z; Zhang Z; Teng Y
    EBioMedicine; 2020 Jan; 51():102609. PubMed ID: 31915116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.